


PHARMACEUTICAL 2022



Paratek Pharmaceuticals Inc. Rank 274 of 475





PHARMACEUTICAL 2022



Paratek Pharmaceuticals Inc. Rank 274 of 475

The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 189% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is -154%, being 123% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	152,100
Cost of Goods Sold	21,535
Intangible Assets	829
Liabilities, Current	31,297
Liabilities, Non-Current	258,513
Other Assets	30,146
Other Compr. Net Income	-13
Other Expenses	18,008
Other Liabilities	21,846
Other Net Income	54
Property and Equipment	794
Research and Development	30,353
Revenues	130,162
Selling, General and Administrative Expense	119,404

Output Variable	Value in 1000 USD
Assets	183,869
Liabilities	311,656
Expenses	189,300
Stockholders Equity	-127,787
Net Income	-59,084
Comprehensive Net Income	-59,090
Economic Capital Ratio	-154%